Frederic J. Winssinger Sells 282 Shares of USANA Health Sciences, Inc. (USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Frederic J. Winssinger sold 282 shares of the firm’s stock in a transaction on Thursday, July 26th. The shares were sold at an average price of $132.75, for a total value of $37,435.50. Following the sale, the director now directly owns 282 shares of the company’s stock, valued at $37,435.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NYSE USNA opened at $129.75 on Friday. USANA Health Sciences, Inc. has a 52 week low of $52.80 and a 52 week high of $137.95. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of 31.96 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 24th. The company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.11 by $0.25. USANA Health Sciences had a return on equity of 30.56% and a net margin of 7.16%. The business had revenue of $301.50 million during the quarter, compared to the consensus estimate of $278.41 million. During the same quarter last year, the company earned $0.98 EPS. The firm’s revenue was up 17.3% compared to the same quarter last year. equities analysts expect that USANA Health Sciences, Inc. will post 4.9 earnings per share for the current year.

Several equities research analysts recently weighed in on the company. Pivotal Research lowered USANA Health Sciences from a “buy” rating to a “hold” rating and set a $95.00 price objective for the company. in a report on Monday, April 23rd. They noted that the move was a valuation call. ValuEngine raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Finally, TheStreet raised USANA Health Sciences from a “c+” rating to an “a-” rating in a report on Tuesday, April 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $135.00.

Hedge funds and other institutional investors have recently modified their holdings of the business. Robecosam AG bought a new position in USANA Health Sciences in the 1st quarter worth about $126,000. SG Americas Securities LLC bought a new stake in shares of USANA Health Sciences during the 1st quarter valued at about $137,000. CAPROCK Group Inc. bought a new stake in shares of USANA Health Sciences during the 2nd quarter valued at about $214,000. Amalgamated Bank bought a new stake in shares of USANA Health Sciences during the 2nd quarter valued at about $223,000. Finally, RNC Capital Management LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter valued at about $231,000. Institutional investors and hedge funds own 49.75% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Penny Stocks, Risk and Reward Factors

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply